Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease by Zidan, J et al.
Comparison of HER-2 overexpression in primary breast cancer
and metastatic sites and its effect on biological targeting therapy of
metastatic disease
J Zidan*,1,2, I Dashkovsky
3, C Stayerman
4, W Basher
1, C Cozacov
3 and A Hadary
3
1Oncology Unit, Sieff Government Hospital, Safed, Israel;
2Faculty of Medicine, Israel Institute of Technology (Technion), Haifa, Israel;
3Department of
Surgery, Sieff Government Hospital, Safed, Israel;
4Department of Pathology, Sieff Government Hospital, Safed, Israel
HER-2 overexpression, a predictive marker of tumour aggressiveness and responsiveness to therapy, occurs in 20–30% of breast
cancer. Although breast cancer is a heterogeneous disease, HER-2 measurement is carried out in primary tumour. This study aims to
evaluate HER-2 overexpression in primary and metastases and its effect on treatment decisions. Biopsies from primary breast cancer
and corresponding metastases from 58 patients were studied. HER-2 overexpression was evaluated immunohistochemically in all
primary and metastatic sites. Positive overexpression in primary and/or metastases was confirmed by fluorescence in situ hybridisation
(FISH). Discordance in HER-2 overexpression between primary and metastatic sites was 14% (eight of 58 patients). Concordance
was found in 50 (86%) of patients (95% CI: 77–95). In one patient (2%), HER-2 was negative in metastasis but positive in primary. In
seven (12%) patients, HER-2 was positive in metastases and negative in primary (95% CI: 3.7–20), and three of them responded to
trastuzumab. Gene amplification by FISH was found in all cases with HER-2 positive (þ2 and þ3) by immunohistochemistry. Our
data suggest that a possible discordance of HER-2 overexpression between primary and metastases should be considered when
making treatment decisions in patients with primary HER-2-negative tumours.
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The choice of therapy for treatment of breast cancer is based on
tumour stage, histopathologic features, hormone receptor status
and biological markers (Hamilton and Piccart, 2000). The most
promising biological marker in terms of predicative value for
breast cancer treatment is HER-2 (Thor et al, 1998). The HER-2
oncoprotein is a transmembrane receptor, belonging to the
epidermal growth factor receptor family, with tyrosine kinase
activity, resulting in intracellular signalling and activation of genes
involved in cell growth, which is associated with shortened
survival, enhanced aggressiveness and other poor prognostic
factors (Slamon et al, 1987; Tsuda et al, 1989). Most of the
literature reports a correlation between HER-2 overexpression and
increased sensitivity to anthracycline-based chemotherapy in
comparison with CMF and tamoxifen (Elledge et al, 1998; Paik
et al, 1998). Most importantly, HER-2 overexpression identifies the
subset of patients who can benefit from trastuzumab, recombinant
humanised anti-HER-2 monoclonal antibody (Genentech Inc.,
South San Francisco, CA, USA), in advanced and metastatic breast
cancer (MBC) (Hortobagyi, 2001; Lohrisch and Piccart, 2001).
Monotherapy with trastuzumab has yielded response rates of 35%
when given as first-line therapy and 18% in patients previously
treated with chemotherapy (Cobleigh, 1999; Vogel et al, 2001).
Compared with chemotherapy alone, combination of chemother-
apy and trastuzumab improves response rates and overall survival
for women with HER-2-positive MBC (Lohrisch and Piccart, 2001).
Breast cancer is a heterogeneous tumour with high individual
variability as far as response to treatment is concerned (Harris
et al, 1997).
Generally, assessment of HER-2 is performed in the primary
tumour even if the metastases appear several years later. As biopsy
of metastases is not routine, it is difficult to test a large number
of cases. Clinical metastases may grow from micrometastases
resistant to adjuvant therapy and may represent one particularly
aggressive clone from among many clones of primary breast cancer
(Harris et al, 1997). It is still unknown whether HER-2 expression
differs in metastases compared to primary breast cancer. Few data
have been published regarding this issue (Cardoso et al, 2001).
The objective of the present study is to determine the expression
of HER-2 in the primary breast cancer and its metastases and to
update our previous results by studying additional patients (Zidan
et al, 2002). All tumours and their metastases were evaluated for
HER-2 using immunohistochemistry (IHC) (Hercept Test). The
fluorescence in situ hybridisation (FISH) test was utilised for HER-
2-overexpressing cases. In addition, we examined the utility of
evaluating HER-2 overexpression in metastases on the decision to
treat these patients with trastuzumab. A comprehensive review of
the literature was also performed.
MATERIALS AND METHODS
Between 1990 and 2002, 209 patients with MBC were treated in our
department. Patients were enrolled in this study if tumour samples
Received 11 January 2005; revised 19 May 2005; accepted 13 July 2005;
published online 16 August 2005
*Correspondence: Dr J Zidan; E-mail: zidan.j@ziv.health.gov.il
British Journal of Cancer (2005) 93, 552–556
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sfrom both primary and corresponding metastases were available
and suitable for IHC analysis. Patients with metastatic ipsilateral
axillary lymph nodes at the primary operation were excluded.
Formalin-fixed paraffin-embedded samples of primary breast
cancer and metastases were collected from 58 patients. For each
case, the primary tumour and the corresponding metastases were
sampled for HER-2 staining at the same time by the same two
experienced pathologists. Immunohistochemical staining for HER-
2 was performed by using CB11 monoclonal antibody with antigen
retrieval. Expression was scored using the scoring system outlined
in the DAKO Hercept Test as 0, 1þ,2þ and 3þ according to the
standardised criteria (Slamon et al, 1989). Gene amplification by
FISH was tested in all cases where the primary tumour or
metastases were positive (þ2o rþ3) by IHC.
Statistical analysis
Rates and positivity were compared using McNamara tests for
paired data. Confidence intervals for concordance/discordance
rates were calculated. The Kendall’s tau-b coefficient was used to
assess concordance for HER-2 status. Although the difference
between HER-2 overexpression in the primary tumour and the
metastases was marginally significant (P¼0.07), a discordance was
observed (Kendall’s tau-b coefficient¼0.69, 95% CI¼0.53–0.80)
due to more cases of HER-2 overexpression in the metastases.
Two-tailed P-values of 0.05 or less was considered to have a
statistical significance.
RESULTS
All 58 cases with available biopsies from the primary tumour and
metastases were included in this study. Median age at diagnosis of
the primary breast cancer was 56 years (range: 29–82 years). One
patient was male. Metastases were found in bone of 68% of patients
(n¼39), in skin and soft tissue in the surgical scar region of 35%
(n¼20), in 36% (n¼21) in liver, in lungs of 33% (n¼19) of
patients and in the pleura of 19% (n¼11) of patients. In 35%
(n¼20) of patients, there was one metastatic site, in 41% (n¼24)
of patients two sites were found and in 24% (n¼14) three
metastases were found (Table 1). Invasive ductal carcinoma was
diagnosed in 88% of patients. Oestrogen and progesterone
receptors (ER, PR) were positive in 60 and 53% of the primary
tumours, respectively. All patients underwent surgery at diagnosis:
60% (n¼35) of patients had lumpectomy and 40% (n¼23) had
mastectomy. In all, 29 (50%) patients were treated with tamoxifen
as adjuvant treatment with or without chemotherapy.
Metastases were diagnosed between 1 and 12 years after primary
breast cancer surgery (median: 4.5 years). HER-2 was positive by
IHC in 24% (n¼14) of the primary breast cancer tissues (two with
2þ and 12 with 3þ) and negative in the remaining 76% (n¼44).
In 35% (n¼20) of patients, HER-2 was positive in metastases (two
with 2þ and 18 with 3þ). Of the total 58 patients, 86% (n¼50)
revealed a concordance between the primary tumour and its
metastases (95% CI: 77–95). In 2% of patients (n¼1), HER-2 was
positive in the primary tumour and negative in the metastatic site.
In 12% (n¼7) of patients, HER-2 was negative in the primary
tumour and positive in the corresponding metastases (95% CI: 3,
7–20) (P¼0.07) (Table 2). The single patient with HER-2 positive
in primary carcinoma of breast and negative in skin and bone
metastases was a 48-year-old woman in whom metastases were
diagnosed 2 years postmastectomy. Trastuzumab and vinorelbine
were given as second-line therapy for 3 months then stopped
because of disease progression.
Four patients were treated with trastuzumab due to HER-2
evaluation in the metastases as follows:
Case 1: A 32-year-old male patient had metastases in skin, bone
and lung 3 years after mastectomy. HER-2 was negative in the
primary tumour but positive in skin and bone metastases. After
failure with doxorubicin and paclitaxel, he received trastuzumab as
a single agent and achieved partial response for 9 months.
Case 2: A 58-year-old woman with primary HER-2 negative but
positive in metastases in liver (after 6 years) received trastuzumab
monotherapy as third-line therapy after chemotherapy failure for 6
months with minimal response and no side effects.
Case 3: A 61-year-old woman had a local recurrence in skin and
soft tissue of chest wall 5 years after mastectomy. Oestrogen
receptor and PR were positive. She received tamoxifen as an
adjuvant treatment for 5 years. At the end of the 5th year, she was
diagnosed with multiple local recurrences in skin and soft tissue.
HER-2 was negative in the primary and positive (þ2) in the
recurrence. Gene amplification by FISH was negative in the
primary and positive in the recurrence. ER and PR were found to
be positive in the recurrence as well. After chemotherapy failure
(two lines), the patient received trastuzumab with vinorelbine
weekly, achieving complete response after 5 months. For the past
13 months, this patient has received only trastuzumab and still in
complete remission with high quality of life.
Case 4: A 52–year-old woman with lung metastases with HER-2
negative in primary and positive in metastases did not respond to
trastuzumab therapy. Three deceased patients who had not
received trastuzumab were studied retrospectively.
DISCUSSION
The most promising predictive factor for breast cancer today is
HER-2. Breast tumours with HER-2 overexpression are resistant to
hormonal therapy and alkylating agents, but more sensitive to
anthracycline-based chemotherapy (Elledge et al, 1998; Ross and
Table 1 Patient characteristics
Number of patients %
Total number of patients 58 100
Gender
Female 57 98
Male 1 2
Age (years)
Median 56
Range 29–82
Receptor status, primary tumour
ER positive 35 60
PR positive 31 53
Primary surgery
Lumpectomy 35 60
Mastectomy 23 40
Histology
Invasive ductal carcinoma 51 88
Invasive lobular carcinoma 7 12
Number of metastatic sites
12 0 3 5
22 4 4 1
31 4 2 4
Prior therapy
Adjuvant chemotherapy 29 50
Adjuvant hormonal therapy 10 18
Adjuvant chemo+hormonal therapy 19 32
ER¼oestrogen receptor; PR¼progesterone receptor.
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sFletcher, 1998; Hamilton and Piccart, 2000). Studies that have
addressed HER-2 as a predictive factor for hormonal therapy have
demonstrated lower response rates or reduced survival in
hormonally treated patients whose tumours overexpressed HER-
2 (level 2þ or 3þ), reaching statistical significance in most
studies (Nicholson et al, 1993; Leitzel et al, 1995; Elledge et al,
1998).
HER-2 overexpression is gaining acceptance as an indicator that
defines breast cancer patients who should preferentially receive
anthracycline-based or CMF adjuvant or therapeutic treatment
(Paik et al, 1998; Thor et al, 1998; Hamilton and Piccart, 2000;
Andrulis et al, 1998). HER-2 overexpression is a prerequisite for
treating patients with MBC with trastuzumab, and may be
considered for adjuvant treatment in the future (Ross and Fletcher,
1998; Baselga, 2001; Eiermann, 2001).
Generally, evaluation of HER-2 overexpression for the treatment
of MBC is carried out in the primary tumour. Overexpression is
shown in 20–77% of human breast cancers (Slichenmyer and
Fry, 2001). Modern diagnostic techniques and tumour markers
can detect metastases without the need for routine biopsy of
metastases. On the other hand, axillary lymph node dissection is
a standard procedure of surgical treatment of breast cancer. This
makes the evaluation of HER-2 in metastases difficult compared
to primary breast cancer and axillary lymph nodes. Most studies
occurred over a period of years because of the difficulty in
recruiting patients (Gancberg et al, 2002). Cardoso et al (2001)
evaluated HER-2 overexpression in primary breast cancer and
metastatic axillary lymph nodes in 370 patients. HER-2 was
positive in 10% of the primary and 11% of the metastases. In all,
98% of these patients revealed a concordance between primary
tumour and lymph nodes.
Distant metastases should not be assumed to be biologically
equivalent to lymph node metastases. Distant metastases are
generally identified years after resection of the primary cancer and
axillary lymph nodes, and represent clonal outgrowths with genetic
modifications not detected in the primary tumour. Additionally,
cells that metastasise via the lymphatic system may possess
biological properties that permit travel to distant sites and
establishment of clinically disseminated disease (Harris et al,
1997).
The present study suggests a 14% discordance of HER-2
overexpression between primary tumour and the metastases
(P¼0.07 McNamara). HER-2 was positive in the primary and
negative in the metastatic site in one patient (2%) and negative in
the primary and positive in metastases in seven patients (12%). In
these seven patients, findings affected the selection of therapy,
particularly by trastuzumab, in four who otherwise would not have
been selected for trastuzumab treatment.
A review of the literature found only 11 studies comparing
HER-2 overexpression in primary breast cancer and metastases
(Table 3). These studies show discordance rates of between 0
and 26%. Niehans et al (1993) retrospectively evaluated HER-2
overexpression in primary breast cancer and different metastatic
sites in autopsy tumour samples. The uncontrolled fixation time of
autopsy samples jeopardises the IHC data that can be obtained
from samples. Masood and Bui (2000) evaluated HER-2 over-
expression in 56 patients, but only 11 cases of metastases were
from distant sites. At the 2000 San Antonio Breast Cancer Meeting,
Edgerton et al (2000) presented preliminary results of a study
comparing HER-2 status in 193 patients, only 93 of which were
distant metastases. Only seven of the 21 metastatic samples
evaluated by Shimizu et al (2000) were from distant sites. Tanner
et al (2001) reported on 46 primary breast cancers and their
metastases. Only 12 of the 46 cases were metastases from distant
sites. Gancberg et al (2002) utilised both IHC and FISH techniques
retrospectively in 107 patients between 1991 and 1999. Only 68 out
of the 107 cases were available for FISH test and five (7%) of them
were discordant. In our previous study, 40 patients with primary
and metastases were evaluated by IHC test. Discordance was found
in 18% of cases (Zidan et al, 2002) and in 14% when 58 patients
were evaluated using both IHC and FISH (Zidan et al, 2004).
Dowsett et al (2003) reported on 8% discordance. In the study
presented by Lipton et al (2003), serum was obtained at the time of
disease progression from 240 patients who were initially serum
HER-2 negative at the start of hormone therapy. In 62 (26%) of 240
patients, serum HER-2 converted from negative to positive at the
time of disease progression. Luftner et al (2004) found discord-
ance in 18% of 80 cases using IHC. An analysis of the studies
summarised in Table 3 shows that the seven studies with the
largest number of patients found discordance to be X7 to 26% and
Table 2 Comparison of 21 patients with HER-2 positive in primary breast cancer and/or metastatic site
Case #
HER-2 (IHC) in
primary
HER-2 (FISH) in
primary Metastatic site
HER-2 (IHC) in
metastases
HER-2 (FISH) in
metastases
1 +3 Positive Skin, soft tissue +3 Positive
2 +3 Positive Skin, bone +3 Positive
3 +3 Positive Local recurrence in
breast
+3 Positive
4 +3 Positive Pleura +3 Positive
5 +3 Positive Liver +3 Positive
6 +3 Positive Liver +3 Positive
7 +2 Positive Lung +3 Positive
8 +3 Positive Skin +3 Positive
9 +3 Positive Bone +2 Positive
10 +3 Positive Lung +3 Positive
11 +2 Positive Bone +3 Positive
12 +3 Positive Skin +3 Positive
13 +3 Positive Liver +3 Positive
14 +3 Positive Skin and bone Negative Negative
15 Negative Negative Skin, soft tissue +3 Positive
16 Negative Negative Soft tissue, bone +3 Positive
17 Negative Negative Skin, bone, lung +3 Positive
18 Negative Negative Liver +3 Positive
19 Negative Negative Skin, soft tissue +2 Positive
20 Negative Negative Pleura +3 Positive
21 Negative Negative Lung +3 Positive
IHC¼immunohistochemistry; FISH¼fluorescence in situ hybridisation.
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sfour studies showed a discordance rate of 0–3%. These four
studies were actually based on small numbers of distant metastases
and include mostly locoregional relapses.
Immunohistochemistry staining has certain limitations, this
cannot, however, explain the discordance observed between
primary and metastases in the expression of HER-2 in the present
study. The same IHC method was used for all patients and
evaluation was carried out by the same pathologist. Primary and
metastatic lesions from the same patients were immunostained in
the same staining run, thus the probability of error is minimised.
The best method of measuring HER-2 is a point of controversy.
A consensus conference was held in August 1999 in an attempt to
resolve some of these issues (Author unlisted, 1999). Data
presented at that meeting indicate that the concordance between
IHC and FISH methods is in the range of 80–90%, comparing 3þ
overexpression. As the median time between primary tumour and
metastases in our study is 4.5 years, it is difficult to compare HER-
2 overexpression by using frozen tissue samples from both
primary and metastases. This technical limitation may affect the
results of IHC test for HER-2 expression in some cases. FISH
technique was used for testing and confirming all cases with HER-
2 overexpression by IHC (þ2 and þ3). All cases in our study
showed amplification by FISH. The first limitation of FISH is the
much higher cost when compared to IHC test. The second
limitation is that, although IHC can be carried out in nearly every
pathology laboratory, FISH can be performed only in special
laboratories with specialised equipment.
The present study is one of the first to address the issue of
heterogeneity between breast cancer primaries and metastatic
sites. The rationale behind the present study is the fact that breast
cancer is a biologically and genetically heterogeneous tumour that
contains multiple different clones (Teixeira et al, 1995). An early
stem line clone may migrate to the metastatic site and grow
independently from its counterpart in the primary tumour,
resulting in complete heterogeneity between primary and meta-
static sites in the same patient. Heterogeneity between primary and
metastatic sites may also result from the genetic instability of
cancer cells. Breast cancer cells that survive adjuvant treatment
may undergo genetic changes resulting in either a loss or gain
of expression of some biological markers (Kuukasjarvi et al,
1997). Molecular changes, including upregulation of HER-2, were
observed in breast cancer relapsing after adjuvant hormone
therapy (Slichenmyer and Fry, 2001; Tanner et al, 2001). In our
study, four of seven patients with HER-2 positive in metastases and
negative in the primary initially received adjuvant treatment with
tamoxifen before developing metastases. Two became ER negative
in metastases. Additionally, some small clones in the primary
tumour overexpress HER-2, but are negligible in the tumour mass
and may not be detected in the staining of the larger primary
breast cancer. Metastases developing from such clones are HER-2
positive (Teixeira et al, 1995).
In all, 12% of patients in the current study were found to be
eligible for treatment with trastuzumab, according to results of
HER-2 overexpression in metastatic sites. To our knowledge, ours
is the first study to address the possibility of treating patients with
metastases of breast cancer with trastuzumab based on the
discordance in HER-2 overexpression between primary tumour
and metastases.
Three other techniques appear easy and applicable in evaluating
HER-2 overexpression in MBC. One promising method is the
testing of extracellular domain of HER-2 in serum of breast cancer
patients (Burstein et al, 2003). Another technique is the evaluation
of HER-2 amplification by chromogenic in situ hybridisation. This
technique is easy, inexpensive and can be carried out in most
hospitals (Dandachi et al, 2004). HER-2 amplification detected by
FISH in fine-needle aspiration (FNA) from metastases is also a
promising technology. Bozzetti et al (2002) evaluate HER-2
amplification by FISH on 66 breast cancer FNAs. Paired results
by FISH cytology and FISH histology showed a concordance of
91%. They concluded that HER-2 gene amplification can be
reliably estimated by FISH on breast cancer FNAs. This makes the
evaluation of HER-2 from metastases easy and implementable.
To summarise, the present study demonstrates a relatively high
discordance rate (14%) in HER-2 overexpression between primary
and metastases of the same breast cancer, emphasising the
existence of biological differences between primary and metas-
tases. We suggest taking HER-2 evaluation into consideration in
metastatic sites when HER-2 is negative in the primary tumour and
the patient can benefit from treatment with trastuzumab.
Additional studies with larger numbers of patients are needed to
verify our results.
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